Comparison 1. RT vs. CT.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 overall survival | 3 | 415 | Peto Odds Ratio (99% CI) | 1.17 [0.85, 1.62] |
| 1.1 early stages | 2 | 299 | Peto Odds Ratio (99% CI) | 1.03 [0.69, 1.52] |
| 1.2 advanced stages | 1 | 116 | Peto Odds Ratio (99% CI) | 1.52 [0.87, 2.66] |
| 2 OS ‐ early stages ‐ sex | 2 | 299 | Peto Odds Ratio (99% CI) | 0.99 [0.67, 1.47] |
| 2.1 female | 2 | 165 | Peto Odds Ratio (99% CI) | 0.78 [0.45, 1.35] |
| 2.2 male | 2 | 134 | Peto Odds Ratio (99% CI) | 1.27 [0.72, 2.25] |
| 3 OS ‐ advanced stages ‐ sex | 1 | 115 | Peto Odds Ratio (99% CI) | 1.54 [0.88, 2.70] |
| 3.1 female | 1 | 47 | Peto Odds Ratio (99% CI) | 1.65 [0.65, 4.19] |
| 3.2 male | 1 | 68 | Peto Odds Ratio (99% CI) | 1.49 [0.74, 2.98] |
| 4 progression free survival | 3 | 415 | Peto Odds Ratio (99% CI) | 0.99 [0.74, 1.32] |
| 4.1 early stages | 2 | 299 | Peto Odds Ratio (99% CI) | 0.97 [0.69, 1.37] |
| 4.2 advanced stages | 1 | 116 | Peto Odds Ratio (99% CI) | 1.03 [0.61, 1.73] |
| 5 PFS ‐ censored at cut‐off date | 3 | 415 | Peto Odds Ratio (99% CI) | 1.00 [0.75, 1.34] |
| 5.1 early stages | 2 | 299 | Peto Odds Ratio (99% CI) | 0.99 [0.69, 1.40] |
| 5.2 advanced stages | 1 | 116 | Peto Odds Ratio (99% CI) | 1.04 [0.61, 1.76] |
| 6 PFS ‐ early stages ‐ sex | 2 | 299 | Peto Odds Ratio (99% CI) | 0.96 [0.68, 1.36] |
| 6.1 female | 2 | 165 | Peto Odds Ratio (99% CI) | 0.66 [0.40, 1.07] |
| 6.2 male | 2 | 134 | Peto Odds Ratio (99% CI) | 1.43 [0.87, 2.36] |
| 7 PFS ‐ advanced stages ‐ sex | 1 | 115 | Peto Odds Ratio (99% CI) | 1.02 [0.60, 1.71] |
| 7.1 female | 1 | 47 | Peto Odds Ratio (99% CI) | 1.01 [0.44, 2.31] |
| 7.2 male | 1 | 68 | Peto Odds Ratio (99% CI) | 1.02 [0.52, 2.00] |
| 8 second malignancy free survival | 3 | 415 | Peto Odds Ratio (99% CI) | 2.12 [0.81, 5.55] |
| 8.1 early stages | 2 | 299 | Peto Odds Ratio (99% CI) | 3.37 [1.01, 11.20] |
| 8.2 advanced stages | 1 | 116 | Peto Odds Ratio (99% CI) | 0.92 [0.18, 4.62] |
| 9 SM before progression/relapse | 3 | 415 | Peto Odds Ratio (99% CI) | 1.99 [0.54, 7.37] |
| 9.1 early stages | 2 | 299 | Peto Odds Ratio (99% CI) | 4.02 [0.70, 23.22] |
| 9.2 advanced stages | 1 | 116 | Peto Odds Ratio (99% CI) | 0.82 [0.11, 5.86] |
| 10 SM free survival ‐ early stages ‐ sex | 2 | 299 | Peto Odds Ratio (99% CI) | 3.12 [0.91, 10.67] |
| 10.1 female | 2 | 165 | Peto Odds Ratio (99% CI) | 4.63 [0.60, 35.73] |
| 10.2 male | 2 | 134 | Peto Odds Ratio (99% CI) | 2.49 [0.53, 11.63] |
| 11 SM free survival ‐ advanced stages ‐ sex | 1 | 115 | Peto Odds Ratio (99% CI) | 0.87 [0.17, 4.35] |
| 11.1 female | 1 | 47 | Peto Odds Ratio (99% CI) | 0.44 [0.04, 4.28] |
| 11.2 male | 1 | 68 | Peto Odds Ratio (99% CI) | 1.72 [0.18, 16.76] |